Global X Autonomous & Electric Vehicles vs Edwards Lifesciences Corporation Common Stock — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.76 (market cap $356.37M), while Edwards Lifesciences Corporation Common Stock trades at $83.98 (market cap $48.56B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 136.3× Global X Autonomous & Electric Vehicles's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| DRIV | EW | |
|---|---|---|
Market Cap | $356.37M | $48.56B |
Volume | 22,397 | 6,520,488 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $95.18 |
52-Week Low | $27.58 | $72.65 |
Typical Hold Time | 40 Days | — |
Enterprise Value | — | $45.01B |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →